Gainers & Losers Of May 30: PTGX, ECYT, NTLA, EDIT, CNCE...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of May 30, 2017.

GAINERS

1. Protagonist Therapeutics Inc. (PTGX)

Gained 43.80% to close Tuesday's (May 30) trading at $11.82.

News: The Company has entered into a worldwide agreement worth $990 million with Johnson & Johnson's subsidiary, Janssen Pharmaceuticals Inc., to co-develop and commercialize PTG-200 for inflammatory bowel disease.

As part of the agreement, Protagonist will grant Janssen exclusive, worldwide rights to PTG-200, a first-in-class oral peptide IL-23 receptor antagonist currently in pre-clinical development. PTG-200 is expected to enter Phase 1 clinical testing in normal healthy volunteers in the second half of 2017.

Protagonist is all set to receive a $50 million upfront payment and potentially up to an additional $940 million in development, regulatory, and sales milestones.

Protagonist Therapeutics and Janssen will jointly conduct the development of PTG-200 through Phase 2 clinical proof-of-concept in Crohn's disease, after which time Janssen will be responsible for development and commercialization. The transaction is expected to close in the third quarter of 2017.

2. Endocyte Inc. (ECYT)

Gained 10.53% to close Tuesday's trading at $2.73.

News: No news

Near-term catalysts:

-- Updated data will be presented from a phase I study of EC1456 in patients with advanced solid tumors (Part A) and FR-positive NSCLC (Part B) on June 5, 2017. -- An update also will be provided for a phase I study of EC1169 in patients with metastatic castration-resistant prostate cancer (mCRPC) on June 5, 2017.

LOSERS

1. Intellia Therapeutics Inc. (NTLA)

Lost 14.24% to close Tuesday's trading at $11.38.

News: A research paper titled, "Unexpected mutations after CRISPR-Cas9 editing in vivo" has unnerved investors of gene editing companies like Intellia.

In a study conducted on mice that had undergone CRISPR gene editing, when their entire genome was sequenced, the researchers found that hundreds of unintended mutations have been introduced into the genome.

Stephen Tsang, co-author of the study, said, " Researchers who aren't using whole genome sequencing to find off-target effects may be missing potentially important mutations. Even a single nucleotide change can have a huge impact."

2. Egalet Corp. (EGLT)

Lost 13.96% to close Tuesday's trading at $2.28.

News: No news

Recent event:

On May 10, 2017, the Company reported financial results for the first quarter ended March 31, 2017.

Net loss for Q1, 2017 was $25.4 million or $1.02 per share on total net revenue of $5.4 million. This compared with a net loss of $18.5 million or $0.76 per share and revenue of $2.7 million for the quarter ended March 31, 2016.

As of March 31, 2017, Egalet had cash and marketable securities totaling $105.3 million.

3. Trevena Inc. (TRVN)

Lost 13.36% to close Tuesday's trading at $2.40.

News: No news

Anticipated event:

Submit NDA for OLINVO for the management of moderate-to-severe acute pain in Q4, 2017.

4. Editas Medicine Inc. (EDIT)

Lost 11.97% to close Tuesday's trading at $13.75.

News: A research paper titled, "Unexpected mutations after CRISPR-Cas9 editing in vivo" has unnerved investors of gene editing companies like Editas.

In a study conducted on mice that had undergone CRISPR gene editing, when their entire genome was sequenced, the researchers found that hundreds of unintended mutations have been introduced into the genome.

Stephen Tsang, co-author of the study, said, " Researchers who aren't using whole genome sequencing to find off-target effects may be missing potentially important mutations. Even a single nucleotide change can have a huge impact."

5. NewLink Genetics Corp. (NLNK)

Lost 9.21% to close Tuesday's trading at $13.02.

News: No news

Near-term catalysts:

-- Data from phase 2 clinical trial of Indoximod in metastatic pancreatic cancer to be presented at ASCO on Monday, June 5, 2017 -- Indoximod in combination with gemcitabine + ABRAXANE Phase 2 trial to be presented at an upcoming medical meeting in the second half of 2017 -- Interim data from a Phase 1b dose-escalation study of Indoximod in combination with standard of care chemotherapy for patients with newly diagnosed acute myeloid leukemia to be presented second half of 2017.

6. Concert Pharmaceuticals Inc. (CNCE)

Lost 8.88% to close Tuesday's trading at $12.01.

News: The Company's CFO Ryan Daws will be leaving in early June 2017 to return to investment banking.

Daws served as CFO of Concert since January 2014. He will continue to consult with the Company, including through the closing of the pending asset purchase agreement with Vertex Pharmaceuticals Inc.